NewsRx

Search our medical news database

Cancer

Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows

Published in Cancer Weekly, April 7th, 2009

A new study shows no increased cancer risk with ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to cancer rates of other powerful lipid-lowering statin therapies. The study, conducted by Tufts Medical Center lipid and health policy experts, was published in the April issue of the Journal of Clinical Lipidology (www.lipidjournal.com).

"This real-world examination shows no increased risk to patients taking ezetimibe alone or the ezetimibe/simvastatin combination to lower their lipid levels -- an issue that sparked many policy and health safety conversations," said lipidologist Richard Karas, MD, PhD, Professor of Medicine, Tufts University School...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook